Latest Pharma Insights
Lilly’s Soaring Sales Growth Offset Slightly By Foundayo Sluggishness
Lilly posted 48% year-over-year revenue growth and increased its incretin market share edge over Novo Nordisk, but the Danish firm continues to win the oral GLP-1 fight with Wegovy pill.
Scrip - August 5, 2026
Lilly posted 48% year-over-year revenue growth and increased its incretin market share edge over Novo Nordisk, but the Danish firm continues to win the oral GLP-1 fight with Wegovy pill.
Scrip - August 5, 2026
Perrigo Maintains Guidance After Q2 Slump With Interim CEO ‘Rebuilding Trust With Investors’
Albert Manzone makes clear he’s comfortable in and qualified for Perrigo’s helm when it announced reported second-quarter net sales down 3.2% to $1.02bn. “We have a clear path to rebuilding trust with investors to consistent execution,” he says.
HBW Insight - August 5, 2026
Albert Manzone makes clear he’s comfortable in and qualified for Perrigo’s helm when it announced reported second-quarter net sales down 3.2% to $1.02bn. “We have a clear path to rebuilding trust with investors to consistent execution,” he says.
HBW Insight - August 5, 2026
US FDA Details Inspection ‘Right-Sizing’ Approach
The agency created an Inspectional Affairs Council to help standardize priorities and align its inspection approach with ‘risk, complexity and public health need.‘
Medtech Insight - August 5, 2026
The agency created an Inspectional Affairs Council to help standardize priorities and align its inspection approach with ‘risk, complexity and public health need.‘
Medtech Insight - August 5, 2026
Finance Watch: Attovia Kicks Off A Potentially Busy Week For Biopharma IPOs
Public Company Edition: Attovia Therapeutics raises $289m in the 16th drug developer IPO in the US in 2026, the first of five first-time offerings expected in the first week of August. Also, Obsidian closes a $350m PIPE alongside Galera reverse merger and Twist prices a $300m FOPO.
Scrip - August 5, 2026
Public Company Edition: Attovia Therapeutics raises $289m in the 16th drug developer IPO in the US in 2026, the first of five first-time offerings expected in the first week of August. Also, Obsidian closes a $350m PIPE alongside Galera reverse merger and Twist prices a $300m FOPO.
Scrip - August 5, 2026
SMID Cap Earnings In Brief: BioNTech, Moderna, Vertex, TG Therapeutics, Rhythm & Travere
The mRNA pioneers continue their efforts to pivot to new growth platforms, Filspari and Imcivree launches are performing well, and business development remains a focus as small and mid-cap companies report Q2 earnings.
Scrip - August 5, 2026
The mRNA pioneers continue their efforts to pivot to new growth platforms, Filspari and Imcivree launches are performing well, and business development remains a focus as small and mid-cap companies report Q2 earnings.
Scrip - August 5, 2026
Obesity Beyond GLP-1s: Myostatins – Too Important To Be Ignored?
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.
In Vivo - August 5, 2026
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.
In Vivo - August 5, 2026
FDA Early Alert: Multiple Injuries, Deaths Associated With Becton Dickinson Intraosseous Needle Sets
The FDA has issued an early alert concerning certain Becton Dickinson Intraosseous Vascular Access System Needle Sets. The agency said 45 serious injuries and four deaths have been associated with the recalled sets, which provide temporary vascular access during emergencies.
Medtech Insight - August 5, 2026
The FDA has issued an early alert concerning certain Becton Dickinson Intraosseous Vascular Access System Needle Sets. The agency said 45 serious injuries and four deaths have been associated with the recalled sets, which provide temporary vascular access during emergencies.
Medtech Insight - August 5, 2026
Stock Watch: Bullish Guidance Is The New Window-Dressing
Roche and AstraZeneca both had Q2 challenges, from currency headwinds to pipeline setbacks and weak products sales, then bullish guidance sent their stocks higher anyway.
Scrip - August 5, 2026
Roche and AstraZeneca both had Q2 challenges, from currency headwinds to pipeline setbacks and weak products sales, then bullish guidance sent their stocks higher anyway.
Scrip - August 5, 2026
Deeper Consumer Insights, E-Commerce Expansion: How Bayer Is Navigating ‘Challenging’ US Market
Bayer Consumer Health saw North America Q2 sales fall 6% amid weak consumer sentiment. The company is responding with deeper consumer insights, pack-price optimization and e-commerce expansion to drive US household penetration.
HBW Insight - August 5, 2026
Bayer Consumer Health saw North America Q2 sales fall 6% amid weak consumer sentiment. The company is responding with deeper consumer insights, pack-price optimization and e-commerce expansion to drive US household penetration.
HBW Insight - August 5, 2026
Podcast: China’s Evolving Role in Global Clinical Development
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 5, 2026
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 5, 2026
Xeltis Says It Has The Money To Pursue FDA Approval — Just Not For What Comes After
Xeltis has closed €70m in combined financing to pursue FDA approval for its bioresorbable dialysis access graft, but chief executive Eliane Schutte was candid that the money funds the regulatory path — not the commercial one.
Medtech Insight - August 5, 2026
Xeltis has closed €70m in combined financing to pursue FDA approval for its bioresorbable dialysis access graft, but chief executive Eliane Schutte was candid that the money funds the regulatory path — not the commercial one.
Medtech Insight - August 5, 2026
Novo Nordisk Weighs Bolt-On Deals As It Looks Past R&D Setbacks
Novo Nordisk CEO Mike Doustdar is signaling bolt-on acquisitions to shore up a pipeline hit by recent trial failures.
Scrip - August 5, 2026
Novo Nordisk CEO Mike Doustdar is signaling bolt-on acquisitions to shore up a pipeline hit by recent trial failures.
Scrip - August 5, 2026
Opdivo Biosimilars Gain Ground After EPO Appeal Defeat
BMS has lost its appeal over an Opdivo melanoma dosing patent before the European Patent Office’s Technical Board of Appeal, removing a potential barrier to European biosimilars.
Generics Bulletin - August 5, 2026
BMS has lost its appeal over an Opdivo melanoma dosing patent before the European Patent Office’s Technical Board of Appeal, removing a potential barrier to European biosimilars.
Generics Bulletin - August 5, 2026
Oncology 505(b)(2)s Need Clear Benefits To Win Uptake
In an exclusive interview with Generics Bulletin, McKesson’s Jessica White explains why oncology 505(b)(2) hybrid products need meaningful clinical, operational or supply advantages – alongside early commercial planning – to win provider uptake.
Generics Bulletin - August 5, 2026
In an exclusive interview with Generics Bulletin, McKesson’s Jessica White explains why oncology 505(b)(2) hybrid products need meaningful clinical, operational or supply advantages – alongside early commercial planning – to win provider uptake.
Generics Bulletin - August 5, 2026
Amneal Raises Annual Guidance Amidst Its ‘Most Transformative Period’
As strong complex generic product performance and new launches drive its affordable medicines segment, Amneal has raised its annual revenue guidance for the second time in 2026.
Generics Bulletin - August 5, 2026
As strong complex generic product performance and new launches drive its affordable medicines segment, Amneal has raised its annual revenue guidance for the second time in 2026.
Generics Bulletin - August 5, 2026
ImmunoAct’s CAR-T Real-World Report Card: Durable Remissions, 98% MSR
ImmunoAct’s NexCAR19 delivers outcomes comparable to Western CAR-Ts at a fraction of the cost. Co-founder Dr Atharva Karulkar breaks down the real-world evidence — drawn from the largest CAR-T dataset in India to date — and the scalable model behind it.
Scrip - August 5, 2026
ImmunoAct’s NexCAR19 delivers outcomes comparable to Western CAR-Ts at a fraction of the cost. Co-founder Dr Atharva Karulkar breaks down the real-world evidence — drawn from the largest CAR-T dataset in India to date — and the scalable model behind it.
Scrip - August 5, 2026
The Federated Learning Wave: Part 2, Beyond Proof of Concept
The engineering, science and deal-making that will determine whether federated learning transforms biopharma AI or stalls again.
In Vivo - August 5, 2026
The engineering, science and deal-making that will determine whether federated learning transforms biopharma AI or stalls again.
In Vivo - August 5, 2026
Hengrui Eyes Fresh NDA For Mounjaro Rival After Second Phase III Diabetes Win
Hengrui’s GLP-1/GIP candidate ribupatide has scored a second win in a late-stage trial in pretreated type 2 diabetes, showing non-inferiority versus Ozempic.
Scrip - August 5, 2026
Hengrui’s GLP-1/GIP candidate ribupatide has scored a second win in a late-stage trial in pretreated type 2 diabetes, showing non-inferiority versus Ozempic.
Scrip - August 5, 2026
CagriSema?Setback Takes Shine Off Novo’s FY Forecast Raise
Novo's better-than-expected second-quarter results have given the drugmaker some breathing room, even as a CagriSema miss leaves analysts asking what 2027 could look like.
Scrip - August 5, 2026
Novo's better-than-expected second-quarter results have given the drugmaker some breathing room, even as a CagriSema miss leaves analysts asking what 2027 could look like.
Scrip - August 5, 2026
Eisai Looks Outward As It Fortifies ‘Omics’ Analysis
Eisai has turned to external provider AWS to help power its "omics" research as part of a more biomarker-based approach to disease.
Scrip - August 5, 2026
Eisai has turned to external provider AWS to help power its "omics" research as part of a more biomarker-based approach to disease.
Scrip - August 5, 2026
BMS Likely Main APAC Beneficiary Of Any AstraZeneca Merger
The possible combination of AstraZeneca and Bristol Myers Squibb would create an APAC powerhouse - albeit one led by the UK party to the possible transaction.
Scrip - August 5, 2026
The possible combination of AstraZeneca and Bristol Myers Squibb would create an APAC powerhouse - albeit one led by the UK party to the possible transaction.
Scrip - August 5, 2026
Amgen Readies Phase III Readouts To Offset Declines In I&I Portfolio
With Otezla sales falling after competing oral psoriasis drug launches and Enbrel continuing its slow decline, attention turns to Phase III dazodalibep in Sjogren’s disease and other programs.
Scrip - August 5, 2026
With Otezla sales falling after competing oral psoriasis drug launches and Enbrel continuing its slow decline, attention turns to Phase III dazodalibep in Sjogren’s disease and other programs.
Scrip - August 5, 2026
Lilly’s Soaring Sales Growth Offset Slightly By Foundayo Sluggishness
Lilly posted 48% year-over-year revenue growth and increased its incretin market share edge over Novo Nordisk, but the Danish firm continues to win the oral GLP-1 fight with Wegovy pill.
Scrip - August 5, 2026
Lilly posted 48% year-over-year revenue growth and increased its incretin market share edge over Novo Nordisk, but the Danish firm continues to win the oral GLP-1 fight with Wegovy pill.
Scrip - August 5, 2026
Finance Watch: Attovia Kicks Off A Potentially Busy Week For Biopharma IPOs
Public Company Edition: Attovia Therapeutics raises $289m in the 16th drug developer IPO in the US in 2026, the first of five first-time offerings expected in the first week of August. Also, Obsidian closes a $350m PIPE alongside Galera reverse merger and Twist prices a $300m FOPO.
Scrip - August 5, 2026
Public Company Edition: Attovia Therapeutics raises $289m in the 16th drug developer IPO in the US in 2026, the first of five first-time offerings expected in the first week of August. Also, Obsidian closes a $350m PIPE alongside Galera reverse merger and Twist prices a $300m FOPO.
Scrip - August 5, 2026
SMID Cap Earnings In Brief: BioNTech, Moderna, Vertex, TG Therapeutics, Rhythm & Travere
The mRNA pioneers continue their efforts to pivot to new growth platforms, Filspari and Imcivree launches are performing well, and business development remains a focus as small and mid-cap companies report Q2 earnings.
Scrip - August 5, 2026
The mRNA pioneers continue their efforts to pivot to new growth platforms, Filspari and Imcivree launches are performing well, and business development remains a focus as small and mid-cap companies report Q2 earnings.
Scrip - August 5, 2026
Stock Watch: Bullish Guidance Is The New Window-Dressing
Roche and AstraZeneca both had Q2 challenges, from currency headwinds to pipeline setbacks and weak products sales, then bullish guidance sent their stocks higher anyway.
Scrip - August 5, 2026
Roche and AstraZeneca both had Q2 challenges, from currency headwinds to pipeline setbacks and weak products sales, then bullish guidance sent their stocks higher anyway.
Scrip - August 5, 2026
Podcast: China’s Evolving Role in Global Clinical Development
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 5, 2026
How shifting perceptions and new opportunities are changing the way sponsors approach China
Scrip - August 5, 2026
Novo Nordisk Weighs Bolt-On Deals As It Looks Past R&D Setbacks
Novo Nordisk CEO Mike Doustdar is signaling bolt-on acquisitions to shore up a pipeline hit by recent trial failures.
Scrip - August 5, 2026
Novo Nordisk CEO Mike Doustdar is signaling bolt-on acquisitions to shore up a pipeline hit by recent trial failures.
Scrip - August 5, 2026
ImmunoAct’s CAR-T Real-World Report Card: Durable Remissions, 98% MSR
ImmunoAct’s NexCAR19 delivers outcomes comparable to Western CAR-Ts at a fraction of the cost. Co-founder Dr Atharva Karulkar breaks down the real-world evidence — drawn from the largest CAR-T dataset in India to date — and the scalable model behind it.
Scrip - August 5, 2026
ImmunoAct’s NexCAR19 delivers outcomes comparable to Western CAR-Ts at a fraction of the cost. Co-founder Dr Atharva Karulkar breaks down the real-world evidence — drawn from the largest CAR-T dataset in India to date — and the scalable model behind it.
Scrip - August 5, 2026
Hengrui Eyes Fresh NDA For Mounjaro Rival After Second Phase III Diabetes Win
Hengrui’s GLP-1/GIP candidate ribupatide has scored a second win in a late-stage trial in pretreated type 2 diabetes, showing non-inferiority versus Ozempic.
Scrip - August 5, 2026
Hengrui’s GLP-1/GIP candidate ribupatide has scored a second win in a late-stage trial in pretreated type 2 diabetes, showing non-inferiority versus Ozempic.
Scrip - August 5, 2026
CagriSema?Setback Takes Shine Off Novo’s FY Forecast Raise
Novo's better-than-expected second-quarter results have given the drugmaker some breathing room, even as a CagriSema miss leaves analysts asking what 2027 could look like.
Scrip - August 5, 2026
Novo's better-than-expected second-quarter results have given the drugmaker some breathing room, even as a CagriSema miss leaves analysts asking what 2027 could look like.
Scrip - August 5, 2026
Eisai Looks Outward As It Fortifies ‘Omics’ Analysis
Eisai has turned to external provider AWS to help power its "omics" research as part of a more biomarker-based approach to disease.
Scrip - August 5, 2026
Eisai has turned to external provider AWS to help power its "omics" research as part of a more biomarker-based approach to disease.
Scrip - August 5, 2026
BMS Likely Main APAC Beneficiary Of Any AstraZeneca Merger
The possible combination of AstraZeneca and Bristol Myers Squibb would create an APAC powerhouse - albeit one led by the UK party to the possible transaction.
Scrip - August 5, 2026
The possible combination of AstraZeneca and Bristol Myers Squibb would create an APAC powerhouse - albeit one led by the UK party to the possible transaction.
Scrip - August 5, 2026
Amgen Readies Phase III Readouts To Offset Declines In I&I Portfolio
With Otezla sales falling after competing oral psoriasis drug launches and Enbrel continuing its slow decline, attention turns to Phase III dazodalibep in Sjogren’s disease and other programs.
Scrip - August 5, 2026
With Otezla sales falling after competing oral psoriasis drug launches and Enbrel continuing its slow decline, attention turns to Phase III dazodalibep in Sjogren’s disease and other programs.
Scrip - August 5, 2026
US FDA Details Inspection ‘Right-Sizing’ Approach
The agency created an Inspectional Affairs Council to help standardize priorities and align its inspection approach with ‘risk, complexity and public health need.‘
Medtech Insight - August 5, 2026
The agency created an Inspectional Affairs Council to help standardize priorities and align its inspection approach with ‘risk, complexity and public health need.‘
Medtech Insight - August 5, 2026
FDA Early Alert: Multiple Injuries, Deaths Associated With Becton Dickinson Intraosseous Needle Sets
The FDA has issued an early alert concerning certain Becton Dickinson Intraosseous Vascular Access System Needle Sets. The agency said 45 serious injuries and four deaths have been associated with the recalled sets, which provide temporary vascular access during emergencies.
Medtech Insight - August 5, 2026
The FDA has issued an early alert concerning certain Becton Dickinson Intraosseous Vascular Access System Needle Sets. The agency said 45 serious injuries and four deaths have been associated with the recalled sets, which provide temporary vascular access during emergencies.
Medtech Insight - August 5, 2026
Xeltis Says It Has The Money To Pursue FDA Approval — Just Not For What Comes After
Xeltis has closed €70m in combined financing to pursue FDA approval for its bioresorbable dialysis access graft, but chief executive Eliane Schutte was candid that the money funds the regulatory path — not the commercial one.
Medtech Insight - August 5, 2026
Xeltis has closed €70m in combined financing to pursue FDA approval for its bioresorbable dialysis access graft, but chief executive Eliane Schutte was candid that the money funds the regulatory path — not the commercial one.
Medtech Insight - August 5, 2026
Perrigo Maintains Guidance After Q2 Slump With Interim CEO ‘Rebuilding Trust With Investors’
Albert Manzone makes clear he’s comfortable in and qualified for Perrigo’s helm when it announced reported second-quarter net sales down 3.2% to $1.02bn. “We have a clear path to rebuilding trust with investors to consistent execution,” he says.
HBW Insight - August 5, 2026
Albert Manzone makes clear he’s comfortable in and qualified for Perrigo’s helm when it announced reported second-quarter net sales down 3.2% to $1.02bn. “We have a clear path to rebuilding trust with investors to consistent execution,” he says.
HBW Insight - August 5, 2026
Deeper Consumer Insights, E-Commerce Expansion: How Bayer Is Navigating ‘Challenging’ US Market
Bayer Consumer Health saw North America Q2 sales fall 6% amid weak consumer sentiment. The company is responding with deeper consumer insights, pack-price optimization and e-commerce expansion to drive US household penetration.
HBW Insight - August 5, 2026
Bayer Consumer Health saw North America Q2 sales fall 6% amid weak consumer sentiment. The company is responding with deeper consumer insights, pack-price optimization and e-commerce expansion to drive US household penetration.
HBW Insight - August 5, 2026
Opdivo Biosimilars Gain Ground After EPO Appeal Defeat
BMS has lost its appeal over an Opdivo melanoma dosing patent before the European Patent Office’s Technical Board of Appeal, removing a potential barrier to European biosimilars.
Generics Bulletin - August 5, 2026
BMS has lost its appeal over an Opdivo melanoma dosing patent before the European Patent Office’s Technical Board of Appeal, removing a potential barrier to European biosimilars.
Generics Bulletin - August 5, 2026
Oncology 505(b)(2)s Need Clear Benefits To Win Uptake
In an exclusive interview with Generics Bulletin, McKesson’s Jessica White explains why oncology 505(b)(2) hybrid products need meaningful clinical, operational or supply advantages – alongside early commercial planning – to win provider uptake.
Generics Bulletin - August 5, 2026
In an exclusive interview with Generics Bulletin, McKesson’s Jessica White explains why oncology 505(b)(2) hybrid products need meaningful clinical, operational or supply advantages – alongside early commercial planning – to win provider uptake.
Generics Bulletin - August 5, 2026
Amneal Raises Annual Guidance Amidst Its ‘Most Transformative Period’
As strong complex generic product performance and new launches drive its affordable medicines segment, Amneal has raised its annual revenue guidance for the second time in 2026.
Generics Bulletin - August 5, 2026
As strong complex generic product performance and new launches drive its affordable medicines segment, Amneal has raised its annual revenue guidance for the second time in 2026.
Generics Bulletin - August 5, 2026
Obesity Beyond GLP-1s: Myostatins – Too Important To Be Ignored?
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.
In Vivo - August 5, 2026
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. After exploring the potential of amylin receptor agonists, we now look at myostatins, which analysts expect to generate peak sales of $30bn.
In Vivo - August 5, 2026
The Federated Learning Wave: Part 2, Beyond Proof of Concept
The engineering, science and deal-making that will determine whether federated learning transforms biopharma AI or stalls again.
In Vivo - August 5, 2026
The engineering, science and deal-making that will determine whether federated learning transforms biopharma AI or stalls again.
In Vivo - August 5, 2026